Literature DB >> 17671778

Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!

Corinna Velik-Salchner, Volker Wenzel, Dirk M Maybauer, Marc O Maybauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17671778     DOI： 10.1007/s00134-007-0783-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  18 in total

1.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

2.  Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.

Authors:  Jean-Christophe Richard; Fabienne Bregeon; Véronique Leray; Didier Le Bars; Nicolas Costes; Christian Tourvieille; Franck Lavenne; Mojgan Devouassoux-Shisheboran; Gerard Gimenez; Claude Guerin
Journal:  Intensive Care Med       Date:  2007-08-02       Impact factor: 17.440

3.  A comparison among animal models of acute lung injury.

Authors:  C Rosenthal; C Caronia; C Quinn; N Lugo; M Sagy
Journal:  Crit Care Med       Date:  1998-05       Impact factor: 7.598

Review 4.  ARDS: clinical lessons from the oleic acid model of acute lung injury.

Authors:  D P Schuster
Journal:  Am J Respir Crit Care Med       Date:  1994-01       Impact factor: 21.405

5.  Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.

Authors:  K Murakami; K Okajima; M Uchiba; M Johno; T Nakagaki; H Okabe; K Takatsuki
Journal:  Am J Physiol       Date:  1997-02

6.  Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.

Authors:  Jerry A Nick; Christopher D Coldren; Mark W Geraci; Katie R Poch; Brian W Fouty; James O'Brien; Michael Gruber; Simona Zarini; Robert C Murphy; Katherine Kuhn; Don Richter; Kelly R Kast; Edward Abraham
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury.

Authors:  Delphine L Chen; Daniel P Schuster
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-05       Impact factor: 5.464

Review 8.  Endogenous protein C activation in patients with severe sepsis.

Authors:  Patricia C Y Liaw
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

9.  Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.

Authors:  K Murakami; K Okajima; M Uchiba; M Johno; T Nakagaki; H Okabe; K Takatsuki
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

10.  Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.

Authors:  Laurent Robriquet; François Collet; Antoine Tournoys; Thierry Prangère; Rémi Nevière; François Fourrier; Benoît P Guery
Journal:  Respir Res       Date:  2006-03-22
View more
  3 in total

Review 1.  [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury].

Authors:  M O Maybauer; S Rehberg; D L Traber; D N Herndon; D M Maybauer
Journal:  Anaesthesist       Date:  2009-08       Impact factor: 1.041

2.  Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.

Authors:  Marc O Maybauer; Dirk M Maybauer; John F Fraser; Csaba Szabo; Martin Westphal; Levente Kiss; Eszter M Horvath; Yoshimitsu Nakano; David N Herndon; Lillian D Traber; Daniel L Traber
Journal:  Crit Care       Date:  2010-11-26       Impact factor: 9.097

Review 3.  Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?

Authors:  Marc O Maybauer; Daniel L Traber; Dirk M Maybauer
Journal:  Crit Care       Date:  2009-01-23       Impact factor: 9.097
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.